Last reviewed · How we verify
FG-M108
FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.
FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Solid tumors (indication under clinical investigation in Phase 3).
At a glance
| Generic name | FG-M108 |
|---|---|
| Also known as | M108 |
| Sponsor | FutureGen Biopharmaceutical (Beijing) Co., Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for FG-M108 are limited in public literature, the drug is being developed by FutureGen Biopharmaceutical as an immunotherapy candidate. Based on the company's pipeline focus, it likely modulates immune checkpoint signaling to reinvigorate T-cell mediated anti-tumor responses, though the precise molecular target requires confirmation from clinical trial data.
Approved indications
- Solid tumors (indication under clinical investigation in Phase 3)
Common side effects
Key clinical trials
- A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FG-M108 CI brief — competitive landscape report
- FG-M108 updates RSS · CI watch RSS
- FutureGen Biopharmaceutical (Beijing) Co., Ltd portfolio CI